Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases

SM Lee, CR Lewanski, N Counsell… - JNCI: Journal of the …, 2014 - academic.oup.com
Background Median survival of non-small cell lung cancer (NSCLC) patients with brain
metastases is poor. We examined concurrent erlotinib and whole brain radiotherapy (WBRT) …
被引用次数：137 相关文章
[PDF] academia.edu

[PDF][PDF] randomized trial of erlotinib Plus Whole-Brain radiotherapy for NSclc Patients With Multiple Brain Metastases

SM Lee, CR Lewanski, N Counsell, C Ottensmeier… - academia.edu
Background Median survival of non-small cell lung cancer (NSCLC) patients with brain
metastases is poor. We examined concurrent erlotinib and whole brain radiotherapy (WBRT) …

Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases

SM Lee, CR Lewanski, N Counsell… - Journal of the …, 2014 - research.manchester.ac.uk
Background Median survival of non-small cell lung cancer (NSCLC) patients with brain
metastases is poor. We examined concurrent erlotinib and whole brain radiotherapy (WBRT) …
[PDF] researchgate.net

[PDF][PDF] randomized trial of erlotinib Plus Whole-Brain radiotherapy for NSclc Patients With Multiple Brain Metastases

SM Lee, CR Lewanski, N Counsell, C Ottensmeier… - researchgate.net
Background Median survival of non-small cell lung cancer (NSCLC) patients with brain
metastases is poor. We examined concurrent erlotinib and whole brain radiotherapy (WBRT) …

Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases

SM Lee, CR Lewanski, N Counsell… - Journal of the …, 2014 - pubmed.ncbi.nlm.nih.gov
Background Median survival of non-small cell lung cancer (NSCLC) patients with brain
metastases is poor. We examined concurrent erlotinib and whole brain radiotherapy (WBRT) …
[HTML] soton.ac.uk

[HTML][HTML] Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases

SM Lee, CR Lewanski, N Counsell… - JNCI Journal of the …, 2014 - eprints.soton.ac.uk
Background: Median survival of non-small cell lung cancer (NSCLC) patients with brain
metastases is poor. We examined concurrent erlotinib and whole brain radiotherapy (WBRT) …
[PDF] core.ac.uk

[PDF][PDF] randomized trial of erlotinib Plus Whole-Brain radiotherapy for NSclc Patients With Multiple Brain Metastases

SM Lee, CR Lewanski, N Counsell, C Ottensmeier… - core.ac.uk
Background Median survival of non-small cell lung cancer (NSCLC) patients with brain
metastases is poor. We examined concurrent erlotinib and whole brain radiotherapy (WBRT) …

Randomized Trial of Erlotinib Plus Whole-Brain Radiotherapy for NSCLC Patients With Multiple Brain Metastases.

SM Lee, CR Lewanski, N Counsell… - JNCI: Journal of the …, 2014 - search.ebscohost.com
Background Median survival of non-small cell lung cancer (NSCLC) patients with brain
metastases is poor. We examined concurrent erlotinib and whole brain radiotherapy (WBRT) …

[引用][C] Randomized Trial of Erlotinib Plus Whole-Brain Radiotherapy for NSCLC Patients With Multiple Brain Metastases

SM LEE, CR LEWANSKI, N COUNSELL… - Journal of the …, 2014 - pascal-francis.inist.fr
Randomized Trial of Erlotinib Plus Whole-Brain Radiotherapy for NSCLC Patients With
Multiple Brain Metastases CNRS Inist Pascal-Francis CNRS Pascal and Francis …
[PDF] scienceopen.com

[PDF][PDF] randomized trial of erlotinib Plus Whole-Brain radiotherapy for NSclc Patients With Multiple Brain Metastases

SM Lee, CR Lewanski, N Counsell, C Ottensmeier… - scienceopen.com
Background Median survival of non-small cell lung cancer (NSCLC) patients with brain
metastases is poor. We examined concurrent erlotinib and whole brain radiotherapy (WBRT) …